Aliskiren: Renin inhibitor for hypertension management

Clinical Therapeutics

Volumn 30, Issue 1, 2008, Pages 31-47

  Cheng, Judy W M ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Aliskiren; cardiovascular outcomes.; diastolic blood pressure; systolic blood pressure

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CELECOXIB; CIMETIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUCONAZOLE; HYDROCHLOROTHIAZIDE; IRBESARTAN; KETOCONAZOLE; LISINOPRIL; LOSARTAN; METOPROLOL; MEVINOLIN; RAMIPRIL; RENIN INHIBITOR; VALSARTAN; WARFARIN;

ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FACE EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; HAND EDEMA; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; LARYNGOPHARYNGITIS; MONOTHERAPY; MUSCLE WEAKNESS; NONHUMAN; PATHOPHYSIOLOGY; PERIORBITAL EDEMA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMIDES; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 45149113838     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.01.011     Document Type: Article

References (49)

1. Rosamond W., Flegal K., Friday G., et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics- 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2007;115:e172]. Circulation 115 (2007) e69-e171
2. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [US Dept of Health and Human Services Web site]. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf Accessed April 10, 2007.
3. Top 300 Prescriptions for 2005 [RxList.com Web site]. http://www.rxlist.com/script/main/art.asp?articlekey=79509 Accessed April 10, 2007.
4. Linn W. Angiotensin-converting enzyme inhibitors in left ventricular dysfunction. Pharmacotherapy 16 (1996) 50S-58S
5. Maggioni A. Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc Drugs Ther 20 (2006) 295-308
6. Hilleman D., and Lucas Jr. B. Angiotensin-converting enzyme inhibitors and stroke risk: Benefit beyond blood pressure reduction?. Pharmacotherapy 24 (2004) 1064-1076
7. Strippoli G., Craig M., Deeks J., et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ (2004) 329:828
8. Greenberg B., Zannad F., and Pitt B. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction. Am J Cardiol 97 (2006) 34F-40F
9. FDA approves new drug treatment for high blood pressure [FDA Web site]. http://www.fda.gov/bbs/topics/NEWS/ 2007/NEW01580.html. Accessed April 15, 2007.
10. Jandeleit-Dahm K., and Cooper M. Hypertension and diabetes: Role of the renin-angiotensin system. Endocrinol Metab Clin North Am 35 (2006) 469-490 vii
11. Dzau V. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 37 (2001) 1047-1052
12. Kostis J. Angiotensin converting enzyme inhibitors. I. Pharmacology. Am Heart J 116 (1988) 1580-1591
13. Mimran A., and Ribstein J. Angiotensin receptor blockers: Pharmacology and clinical significance. J Am Soc Nephrol 10 Suppl 12 (1999) S273-S277
14. Brown N. Eplerenone: Cardiovascular protection. Circulation 107 (2003) 2512-2518
15. Urata H., Kinoshita A., Misono K., et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart [published correction appears in J Biol Chem. 1991;266:12114]. J Biol Chem 265 (1990) 22348-22357
16. Okunishi H., Miyazaki M., and Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 2 (1984) 277-284
17. Hollenberg N., Fisher N., and Price D. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 32 (1998) 387-392
18. Saris J., van Dijk M., Kroon I., et al. Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. Hypertension 35 (2000) 764-768
19. Cruden N., and Newby D. Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?. Am J Cardiovasc Drugs 4 (2004) 345-353
20. Fisher N., and Hollenberg N. Renin inhibition: What are the therapeutic opportunities?. J Am Soc Nephrol 16 (2005) 592-599
21. Azizi M., Webb R., Nussberger J., and Hollenberg N. Renin inhibition with aliskiren: Where are we now, and where are we going?. J Hypertens 24 (2006) 243-256
22. Staessen J., Li Y., and Richart T. Oral renin inhibitors [published correction appears in Lancet. 2006;368: 2124]. Lancet 368 (2006) 1449-1456
23. Nussberger J., Wuerzner G., Jensen C., and Brunner H. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): Comparison with enalapril. Hypertension 39 (2002) E1-E8
24. Azizi M., Ménard J., Bissery A., et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15 (2004) 3126-3133
25. Tekturna (aliskiren) tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2007. http://www.pharma.us.novartis.com/product/pi/pdf/tekturna.pdf. Ac-cessed April 16, 2007.
26. Waldmeier F., Glaenzel U., Wirz B., et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 35 (2007) 1418-1428
27. Zhao C., Vaidyanathan S., Yeh C., et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 45 (2006) 1125-1134
28. Vaidyanathan S., Reynolds C., Yeh C., et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 47 (2007) 453-460
29. Vaidyanathan S., Jermany J., Yeh C., et al. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol 62 (2006) 690-698
30. Vaidyanathan S., Bigler H., Yeh C., et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmaco-kinet 46 (2007) 661-675
31. Vaidyanathan S., Warren V., Yeh C., et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 47 (2007) 192-200
32. Hanssens M., Keirse M., Vankelecom F., and Van Assche F. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obset Gynecol 78 (1991) 128-135
33. Moore N., Dicker P., O'Brien J., et al. Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition. Hypertension 50 (2007) 340-347
34. Fuchs S., Philippe J., Germain S., et al. Functionality of two new polymorphisms in the human renin gene enhancer region. J Hypertens 20 (2002) 2391-2398
35. Dieterle W., Corynen S., Vaidyana-than S., and Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 43 (2005) 527-535
36. Vaidyanathan S., Valencia J., Kemp C., et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 60 (2006) 1343-1356
37. Dieterle W., Corynen S., and Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 58 (2004) 433-436
38. Stanton A., Jensen C., Nussberger J., and O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42 (2003) 1137-1143
39. Kushiro T., Itakura H., Abo Y., et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 29 (2006) 997-1005
40. Gradman A., Schmieder R., Lins R., et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111 (2005) 1012-1018
41. O'Brien E., Barton J., Nussberger J., et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49 (2007) 276-284
42. Villamil A., Chrysant S., Calhoun D., et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25 (2007) 217-226
43. Pool J., Schmieder R., Azizi M., et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 20 (2007) 11-20
44. Oh B., Mitchell J., Herron J., et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 49 (2007) 1157-1163
45. Jordan J., Engeli S., Boye S., et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 49 (2007) 1047-1055
46. Oparil S., Yarows S., Patel S., et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial [published correction appears in Lancet. 2007;370: 1542]. Lancet. 370 (2007) 221-229
47. Aliskiren (Tekturna) [product information] [California Pharmacists Association Web site]. http://cpha-com. web09.winsvr.net/pdf/iRx-California-Tekturna.pdf Accessed January 4, 2008.
48. Prescription price checker [drugstore.com Web site]. http://www.drugstore.com/pharmacy/drugindex/ default.asp?trx=1Z5015. Accessed January 4, 2008.
49. Aliskiren Clinical Trials. http://www.clinicaltrials.gov/ct/action/GetStudy. Accessed September 26, 2007.